← Leaderboards
Chang-Guo Zhan
University Of Kentucky
$31,565,757
Attributed
$39,344,089
Total exposure
15
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,344,089 · 15
By mechanism
R01$18,343,897 · 7
U01$11,763,671 · 1
UH3$4,426,690 · 2
UH2$2,151,322 · 1
UG3$1,065,924 · 1
RC1$951,629 · 1
Top collaborators
- Jun Zhu10 shared
- Jay P Mclaughlin7 shared
- Donald W Landry5 shared
- James H Woods5 shared
- Fang Zheng5 shared
- James M O'Donnell2 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Fang Zheng$2,188,249
- Michael T. Bardo$9,972,439
- Pavel Ivanovich Ortinski$3,770,616
- Jill R. Turner$4,005,452
- Reagan Elizabeth Mayfield Lamb$39,129
Others in their field
Top investigators on “Cocaine”
- Sten H Vermund · University Of Alabama At Birmingham$115,253,143
- Fred M Gordin · Social And Scientific Systems, Inc.$44,160,542
- Eric J Nestler · Icahn School Of Medicine At Mount Sinai$42,690,128
- Joel Gelernter · Washington University$34,364,949
- Michael A Nader · Emory University$33,226,167
- Shenghan Lai · University Of Miami Coral Gables$31,568,530
Research focus
CocaineMutantDesignInvestigationIn VitroMolecularProteinsBaseEnzymesMetabolismIn VivoPharmaceutical PreparationsDoseHydrolysisButyrylcholinesteraseBinding SitesMolecular DynamicsCocaine AbuseNeuronsTreatment StrategyBindingToxic EffectBehavioralStructure
Grant awards (53)
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1Tat and cocaine$728,575
R01 · FY2025 · DA
Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoning$643,949
UH3 · FY2025 · NS
Effects of HIV-1 Tat protein and methamphetamine on VMAT2-mediated dopamine transmission in the context of neuroHIV and drug abuse$642,302
R01 · FY2025 · DA
Ghrelin Deacylase as a Treatment for Opioid Polysubstance Abuse$506,678
R01 · FY2025 · DA · contact PI
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$696,079
R01 · FY2024 · DA
Effects of HIV-1 Tat protein and methamphetamine on VMAT2-mediated dopamine transmission in the context of neuroHIV and drug abuse$642,302
R01 · FY2024 · DA
Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoning$532,962
UG3 · FY2024 · NS
Computational Core$114,974
P20 · FY2024 · GM · contact PI
Effects of HIV-1 Tat protein and methamphetamine on VMAT2-mediated dopamine transmission in the context of neuroHIV and drug abuse$654,552
R01 · FY2023 · DA
Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoning$532,962
UG3 · FY2023 · NS
Computational Core$130,076
P20 · FY2023 · GM · contact PI
Development of a Long-acting Enzyme Therapy for Treatment of Cocaine Abuse$4,721,164
U01 · FY2022 · DA · contact PI
Ghrelin Deacylase as a Treatment for Opioid Polysubstance Abuse$1,700,947
R01 · FY2022 · DA · contact PI
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$515,165
R01 · FY2022 · DA
Computational Core$145,206
P20 · FY2022 · GM · contact PI
Development of a Long-acting Enzyme Therapy for Treatment of Cocaine Abuse$3,521,342
U01 · FY2021 · DA · contact PI
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$515,554
R01 · FY2021 · DA
Computational Core$152,306
P20 · FY2021 · GM · contact PI
Development of a Long-acting Enzyme Therapy for Treatment of Cocaine Abuse$3,521,165
U01 · FY2020 · DA · contact PI
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$515,165
R01 · FY2020 · DA
Computational Core$98,394
P20 · FY2020 · GM · contact PI
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse$811,835
UH3 · FY2019 · DA · contact PI
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$515,554
R01 · FY2019 · DA
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse$1,448,427
UH3 · FY2018 · DA · contact PI
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$537,119
R01 · FY2018 · DA
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse$1,522,479
UH3 · FY2017 · DA · contact PI
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse$1,110,301
UH2 · FY2016 · DA · contact PI
Long-lasting cocaine-metabolizing enzyme for cocaine addiction treatment$1,088,896
R01 · FY2015 · DA · contact PI
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse$1,041,021
UH2 · FY2015 · DA · contact PI
Development of a Cocaine-Metabolizing Enzyme for Drug Overdose Treatment$5,076
R01 · FY2015 · DA · contact PI
Long-lasting cocaine-metabolizing enzyme for cocaine addiction treatment$1,097,704
R01 · FY2014 · DA · contact PI
Development of a Cocaine-Metabolizing Enzyme for Drug Overdose Treatment$610,225
R01 · FY2014 · DA · contact PI
Long-lasting cocaine-metabolizing enzyme for cocaine addiction treatment$1,176,703
R01 · FY2013 · DA · contact PI
Development of a Cocaine-Metabolizing Enzyme for Drug Overdose Treatment$585,816
R01 · FY2013 · DA · contact PI
Development of a Cocaine-Metabolizing Enzyme for Drug Overdose Treatment$6,432
R01 · FY2013 · DA · contact PI
Development of a Cocaine-Metabolizing Enzyme for Drug Overdose Treatment$622,350
R01 · FY2012 · DA · contact PI
High-activity mutants of cocaine esterase for treatment of drug addiction$549,174
R01 · FY2012 · DA · contact PI
High-activity mutants of cocaine esterase for treatment of drug addiction$499,768
R01 · FY2011 · DA · contact PI
High-activity mutants of cocaine esterase for treatment of drug addiction$500,218
R01 · FY2010 · DA · contact PI
Phosphodiesterase-2 and Mood Disorders: Target Validation and Drug Discovery$468,313
RC1 · FY2010 · MH
Redesign of Butyrylcholinesterase for Cocaine Metabolism$345,031
R01 · FY2010 · DA · contact PI
High-activity mutants of cocaine esterase for treatment of drug addiction$489,970
R01 · FY2009 · DA · contact PI
Phosphodiesterase-2 and Mood Disorders: Target Validation and Drug Discovery$483,316
RC1 · FY2009 · MH
Redesign of Butyrylcholinesterase for Cocaine Metabolism$348,516
R01 · FY2009 · DA · contact PI
High-activity mutants of cocaine esterase for treatment of drug addiction$498,945
R01 · FY2008 · DA · contact PI
Redesign of Butyrylcholinesterase for Cocaine Metabolism$348,516
R01 · FY2008 · DA · contact PI
Redesign of Butyrylcholinesterase for Cocaine Metabolism$88,121
R01 · FY2008 · DA · contact PI
Redesign of Butyrylcholinesterase for Cocaine Metabolism$9,549
R01 · FY2008 · DA · contact PI
Redesign of Butyrylcholinesterase for Cocaine Metabolism$355,629
R01 · FY2007 · DA · contact PI
Redesign of Butyrylcholinesterase for Cocaine Metabolism$366,250
R01 · FY2006 · DA · contact PI
Redesign of Butyrylcholinesterase for Cocaine Metabolism$184,125
R01 · FY2005 · DA
Redesign of Butyrylcholinesterase for Cocaine Metabolism$184,125
R01 · FY2004 · DA
Redesign of Butyrylcholinesterase for Cocaine Metabolism$212,766
R01 · FY2003 · DA